GENB — Generate Biomedicines, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2100782 ·
Last close
$9.84
Market Cap
$1.27B
52W High
$22.67
52W Low
$9.73
ADV30
976,158
Next earnings
2026-11-12
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 4,220,000 — -91,507,000 -87,657,000 515,890,000 140,350,000 134,734,000
Jun 2026 6,314,000 — -71,614,000 -67,255,000 561,690,000 135,359,000 105,645,000
Mar 2026 7,224,000 — -64,112,000 -61,446,000 625,737,000 160,575,000 110,936,000
Dec 2025 3,311,000 — -63,949,000 -55,425,000 330,182,000 121,650,000 953,379,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-240,261,000
Investing CF
$-168,159,000
Financing CF
$398,609,000
CapEx
$-5,619,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.74
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-804,994,000
Inventory
—
Receivables
—
ST Investments
$322,056,000
EBIT TTM
$-228,832,000
Pretax Income TTM
$-229,844,000
Interest Exp TTM
$1,012,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$21,069,000
EBITDA
$-277,863,008
Free Cash Flow
—
Enterprise Value
$1,229,325,696
Total Cash
$404,212,000
Total Debt
$75,341,000
Shares Out
129,096,666
Trailing EPS
$-2.44
Book Value
$2.95
ROE
—
ROA
—
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 31,893,000 -235,065,000 -203,154,000 330,182,000 953,379,000 -615,965,000 -200,619,000
Dec 2024 20,459,000 -196,939,000 -173,771,000 518,259,000 953,349,000 -434,519,000 -117,750,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$561,690,000
Forward EPS
$-2.38

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $10.38 · call volume: 73 · put volume: 11
Expected Move to 2027-04-16: ±$4.22 (40.70%) — implied range $6.16 – $14.61 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MLYS Mineralys Therapeutics, Inc. $1.28B $14.48 —
GHRS GH Research PLC $1.25B $18.27 —
AVLN Avalyn Pharma Inc. $1.24B $27.92 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —
INVA Innoviva, Inc. $1.30B $18.30 —

News headlines (Yahoo Finance, 1h cache)

Generate Biomedicines: Q3 Earnings Snapshot
2026-11-12 12:37 · Yahoo
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:20 · Yahoo
Generate Biomedicines (GENB) Stock Looks Fully Priced On Its 17% Jump
2026-10-31 06:18 · Yahoo
Generate Biomedicines to Participate in November Investor Conferences
2026-10-22 11:00 · Yahoo
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
2026-10-14 16:17 · Yahoo
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
2026-10-14 15:30 · Yahoo
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
2026-10-13 20:30 · Yahoo
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
2026-10-13 20:30 · Yahoo
Prologue Medicines Appoints Stephen Harrison, Ph.D., as Chief Scientific Officer
2026-10-13 14:00 · Yahoo
Generate Biomedicines Inc. to Participate in September Investor Conferences
2026-09-08 11:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.